Measles can be a life threatening condition
Keystone
Measles is on the rise in Switzerland with 87 cases of the infectious disease registered so far in 2024. This compares to just 23 cases throughout last year and zero occurrences in 2022 and 2021.
This content was published on
2 minutes
Keystone-SDA
Do you want to read our weekly top stories? Subscribe here.
Since June 2023, there have been 103 cases, according to the bulletin published by the Federal Office of Public Health (FOPH) on Monday. In the same period last year, there were only 27.
The government did not expect a major epidemic because the high vaccination rate should prevent this. According to information from February, the vaccination rate for young children is 94%.
The FOPH assumes that the cases often involve people who were infected abroad or smaller outbreaks in which the pathogen was introduced into Switzerland.
With this increase, Switzerland is part of a global development. The World Health Organization (WHO) expects the number of measles infections to remain high in 2024. According to the latest data, the WHO registered around 94,000 cases up to April 2024.
In 2023, a good 320,000 people were proven to have been infected, an increase of almost 90% compared to the previous year.
According to WHO estimates, 136,000 people died of measles in 2022, mainly children under the age of five. The vast majority of cases do not appear in international statistics.
Measles is a life-threatening, viral infectious disease that can be prevented by vaccination.
Translated from German by DeepL/mga
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Popular Stories
More
Culture
Wealth is not all: how gentrification in Zurich has led to housing shortage
Swisscom receives greenlight for acquisition of Vodafone Italia
This content was published on
The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
EU Commission president says Swiss-EU deal is ‘historic’ agreement
This content was published on
At a joint media conference with Swiss President Viola Amherd in Bern, European Commission President Ursula von der Leyen spoke of a "day of joy".
Switzerland and EU reach deal on future bilateral relations
This content was published on
Switzerland and the European Union have announced a political agreement to update their trading relationship after almost a decade of difficult talks.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.